The success of chimeric antigen receptor (CAR) T-cell therapy in treating hematologic malignancies has generated widespread interest in translating this technology to solid cancers. However, issues like tumor infiltration, the immunosuppressive tumor microenvironment, and tumor heterogeneity limit its efficacy in the solid tumor setting. Recent experimental and clinical studies propose local...
Chimeric Antigen Receptor (CAR) T-cell therapy represents a frontier in treating leukemias and lymphomas, with recent clinical approvals worldwide. Despite its potential, therapeutic outcomes remain heterogeneous due to factors such as limited in vivo persistence, impaired migration, exhausted phenotypes, and tumor-mediated immunosuppression. Mathematical modeling offers a robust framework to...
Antigen Receptor (CAR) T-cell therapy has transformed cancer immunotherapy by genetically engineering T-cells to target tumor antigens. Acute myeloid leukemia (AML) presents unique challenges due to resistance mechanisms, especially in patients with TP53 loss mutations.
The complex dynamics of CAR T-cell expansion remain poorly understood. The field lacks validated quantitative frameworks to...
CAR T-cell therapy, based on genetically engineered T-cells, has demonstrated significant potential in treating hematological malignancies, including B-cell lymphomas. This treatment has complex longitudinal dynamics due to the interplay of different T-cell phenotypes (e.g. effector and memory), the expansion of the drug and the cytotoxic effect on both normal and cancerous B-cells, the...
Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a transformative approach in cancer treatment, particularly for hematological malignancies, and is increasingly explored for solid tumors. Patient responses, however, are highly variable, reflecting the complexity of tumor-immune interactions, antigen heterogeneity, immune exhaustion, and microenvironmental influences.
This...
